WAG
ZVSA

Winthrop Advisory Group’s ZyVersa Therapeutics ZVSA Stock Holding History

Winthrop Advisory Group’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38
Closed -$1.73K – 144
2023
Q3 		$1.73K Hold
38
– – ﹤0.01% 127
2023
Q2 		$3.28K Hold
38
– – ﹤0.01% 134
2023
Q1 		$25.8K Buy
+38
New +$28.4K ﹤0.01% 127

Other funds holding ZVSA

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Winthrop Advisory Group's ZVSA Position: Q4 2023 in Review

Winthrop Advisory Group sold out of ZyVersa Therapeutics (ZVSA) in Q4 2023, closing a stake of 38 shares — an estimated $1.73K sold.

Winthrop Advisory Group first reported a position in ZVSA in Q1 2023 and held it in 3 quarters. The position peaked at $25.8K in Q1 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q4 2023.

  • Winthrop Advisory Group reported no remaining ZyVersa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Winthrop Advisory Group sold 38 ZyVersa Therapeutics shares in Q4 2023, an estimated $1.73K.
  • Winthrop Advisory Group first reported a position in ZyVersa Therapeutics in Q1 2023 and held it in 3 quarters.
  • Winthrop Advisory Group's ZyVersa Therapeutics position peaked at $25.8K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2023.

Based on Winthrop Advisory Group's 13F filing for Q4 2023, filed 10 Jan 2024.